Neogen Corporation

Valuation Analysis

About the Company

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides software systems that help testers analyze and store results; natural toxin tests; rapid sanitation tests; culture and prepared media products; filter tests for micro

Neogen Corporation Stock at a Glance

Neogen Corporation (NEOG) is currently trading at $9.10 with a market capitalization of $2B. The 52-week range spans from $4.56 to $11.43; the current price is 20.4% below the yearly high. Year-over-year revenue growth stands at -4.4%.

💰 Dividend

Neogen Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

3 analysts rate Neogen Corporation (NEOG) on consensus: Buy. The average price target is $12.00, implying +31.87% from the current price. Analyst price targets range from $11.00 to $13.00.

Neogen Corporation: The Investment Case in Detail

Neogen Corporation (NEOG) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Wall Street consensus sits at Buy with an average price target implying roughly 31.87% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Revenue is contracting at -4.4% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valuation in Context

With a PEG ratio of 0.66, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 32.19x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The analyst consensus price target implies 31.87% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Risk Profile

The data points to above-average price swings, elevated short interest (8%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Neogen Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.